Monopar Therapeutics Inc.
Climate Impact & Sustainability Data (2021)
Reporting Period: 2021
Environmental Metrics
Climate Goals & Targets
Short-term Goals:
- Raise additional funding within the next 12 months to complete the Validive Phase 2b/3 clinical trial and support further development of camsirubicin.
Environmental Challenges
- COVID-19 pandemic impacting clinical trials, manufacturing, and fundraising.
- Russia-Ukraine conflict increasing fuel costs and potentially delaying clinical material manufacturing.
- Competition from other biotechnology and pharmaceutical companies.
Mitigation Strategies
- Modified Validive Phase 3 clinical trial to a Phase 2b/3 design to adapt to the COVID-19 environment.
- Monitoring the impact of the COVID-19 pandemic and Russia-Ukraine conflict on operations.
- Leveraging scientific and clinical experience to reduce risk and accelerate clinical development.